These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26695543)

  • 1. [Age- and Gender-specific Costs as Well as Drug Therapies of ADHD Patients].
    Klora M; Zeidler J; Lublow D; Linder R; Verheyen F; von der Schulenburg JM
    Gesundheitswesen; 2016 Jul; 78(7):e23-9. PubMed ID: 26695543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
    Braun S; Russo L; Zeidler J; Linder R; Hodgkins P
    Clin Ther; 2013 May; 35(5):673-85. PubMed ID: 23587606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
    Bachmann CJ; Philipsen A; Hoffmann F
    Dtsch Arztebl Int; 2017 Mar; 114(9):141-148. PubMed ID: 28351466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis.
    Libutzki B; Ludwig S; May M; Jacobsen RH; Reif A; Hartman CA
    Eur Psychiatry; 2019 May; 58():38-44. PubMed ID: 30802682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
    Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
    Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
    Song I; Shin JY
    Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
    Schubert I; Köster I; Lehmkuhl G
    Dtsch Arztebl Int; 2010 Sep; 107(36):615-21. PubMed ID: 20948775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M; Locatelli I; Švab V
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
    Song I; Lee MS; Lee EK; Shin JY
    Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
    Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
    Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
    Secnik K; Swensen A; Lage MJ
    Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.
    Furu K; Karlstad Ø; Zoega H; Martikainen JE; Bahmanyar S; Kieler H; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):373-379. PubMed ID: 27911044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Trends in Stimulant Usage.
    Safer DJ
    J Atten Disord; 2016 Jun; 20(6):471-7. PubMed ID: 26486603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
    Brinker A; Mosholder A; Schech SD; Burgess M; Avigan M
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):328-33. PubMed ID: 17630866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.